Sampatrilat (Compound 14, UK 81252, Figure 4B) functions as a dual-action inhibitor targeting both ACE and NEP and it holds promise for therapeutic use in managing conditions such as hypertension and congestive heart failure (Wallis et al., 1998; Venn et al., 1998b; Venn et al., 1998a). The gene discussed is ACE; the disease is congestive heart failure.